NOV 25, 2021 5:00 AM PST

What's a T Cell COVID Vaccine and Could It Be Better Than What We Have?

WRITTEN BY: Tara Fernandes

All vaccines train the immune system to recognize and wage war against pathogens such as viruses and bacteria. However, vaccines differ in how they deliver the 'training material' and which immune cells they target.

One of the main concerns about the vaccines currently authorized for use (such as the Pfizer/BioNTech and Moderna) is that their immunologic protection could diminish over time. Public health officials say the solution is to administer a vaccine booster dose. 

"Authorizing the use of a single booster dose of either the Moderna or Pfizer-BioNTech COVID-19 vaccine for individuals 18 years of age and older helps to provide continued protection against COVID-19, including the serious consequences that can occur, such as hospitalization and death," said the FDA in an official statement.

However, a newly-developed second-generation vaccine could eliminate the need for boosters by offering sustained, longer-lasting immune protection in those who receive it. This technology, known as a T cell vaccine, is administered as a skin patch. Unlike the current COVID-vaccines, which shield against infection via an antibody response, T cell vaccines activate virus-killing T cells to do the job. As soon as a virus gains entry, T cells rush to the scene and clear them in what scientists are calling "abortive infections."

One of the benefits of the T cell vaccine approach is that it is more resistant to mutational changes in the virus over time. Antibodies work by recognizing specific molecular features on SARS-CoV-2. However, as these features transform due to mutations, antibodies lose sight of their targets, and their activity recedes.

According to Emergex, the drug developer pushing a T cell COVID vaccine towards the clinic, figuring out an optimal delivery mechanism for the vaccine was a challenge. Researchers ended up with a design that uses gold nanoparticles studded with viral proteins that sit on a bed of micro-needles. These are affixed to a small plastic patch applied to the skin's surface, releasing the vaccine's active ingredients in seconds. 

The skin patch has a significant leg up over existing COVID vaccines in terms of how easy it is to distribute widely. The patches are stable at room temperature for up to three months (unlike temperature-sensitive mRNA vaccines that require cold storage).

Interestingly, T cell vaccines have a broad range of potential applications beyond just coronavirus. An ongoing clinical trial is investigating whether T cell vaccines can effectively protect against dengue fever. The drug developer is also looking to use a similar technology to defend against influenza, Zika, and Ebola viruses.

 

About the Author
PhD
Interested in health technology and innovation.
You May Also Like
FEB 08, 2022
Immunology
Biomaterial Makes Cancer Cells 10 Times More Sensitive
FEB 08, 2022
Biomaterial Makes Cancer Cells 10 Times More Sensitive
  Tumors have a sneaky strategy of becoming resistant to chemotherapy drugs—they have a way of “pumping ...
FEB 08, 2022
Health & Medicine
Promising New Myasthenia Gravis Drug Completes Phase 3 Trial
FEB 08, 2022
Promising New Myasthenia Gravis Drug Completes Phase 3 Trial
Zilucoplan, a peptide inhibitor under investigation for the treatment of generalized myasthenia gravis in adults, was fo ...
MAR 10, 2022
Health & Medicine
New Study States Natural Immunity to COVID Lasted up to 15 months in the Majority of Its Cohorts
MAR 10, 2022
New Study States Natural Immunity to COVID Lasted up to 15 months in the Majority of Its Cohorts
From the beginning of the pandemic to late January 2022 during the Omicron wave, the CDC estimates that 43% of the US po ...
MAR 14, 2022
Cancer
Expanded Approval for the PD-1 Blocking Immunotherapy Opdivo
MAR 14, 2022
Expanded Approval for the PD-1 Blocking Immunotherapy Opdivo
Over the past decade, immunotherapy drugs known as immune checkpoint inhibitors have emerged as a promising an ...
APR 01, 2022
Drug Discovery & Development
Pill Form of Remdesivir Treats COVID-19 in Mice
APR 01, 2022
Pill Form of Remdesivir Treats COVID-19 in Mice
A pill form of remdesivir, an antiviral drug currently administered intravenously, may be able to treat COVID-19 in mice ...
MAY 15, 2022
Immunology
Long-Term Antibiotics Raise the Risk of Death From a Systemic Fungal Infection
MAY 15, 2022
Long-Term Antibiotics Raise the Risk of Death From a Systemic Fungal Infection
Infections are common, and many are becoming increasingly hard for clinicians to treat. Antibiotics are often used to tr ...
Loading Comments...